PCSK9 Inhibitor Underuse

Panelists discuss how PCSK9 inhibitors remain underutilized despite their strong efficacy and safety record. The main barriers are cost, prior authorization requirements, and patient hesitancy with injectable formats.

They note that even eligible high-risk patients often abandon therapy due to administrative complexity or affordability.

Panelists call for streamlined access pathways and education to ensure these life-saving agents reach appropriate patients.